When an accident changes your life, we pursue justice for you.

 

CIRCLE OF JUSTICE - Defective Products/Dangerous Drugs

The Margolis Firm PC proudly announces that we are now Affiliated with the prestigious, nationally recognized New York law firm Napoli Bern Ripka Shkolnik LLP

Please consider us for investigating and handling your Defective Products and Dangerous Drug cases involving Actos, Asbestos, DePuy Hip Implants, Lo/Ovral, Lung Cancer, Mesothelioma, Multaq, NuvaRing, Paxil, Plavix, Pradaxa, Propecia, Topamax, Transvaginal Mesh, Yaz or Zoloft.

Actos Litigation:

Actos is a Type 2 diabetes medication (pioglitazone) which has been shown to increase the risk of bladder cancer if used for more than a year. In 2011, the U.S. Food and Drug Administration (FDA) requested a change in Actos labeling reflecting this information. In addition to the FDA’s Drug Safety Communication regarding prolonged use of Actos and an increased risk of bladder cancer, there also was a 2007 FDA Safety Alert concerning heart risks associated with pioglitazone. The updated label included a "boxed warning" emphasizing that pioglitazone may cause or exacerbate health failure. If you have been prescribed Actos and are concerned about the risks of bladder cancer, it is important to speak with your healthcare provider before changing treatment or stopping your medication.

Actos, manufactured by Takeda, has been under FDA review since September 2010. In June 2011, the FDA issued a warning for Actos, while at the same time drug regulators in France and Germany suspended use of the drug. The Margolis Firm PC is interested in bladder cancer claims involving usage of Actos, Actoplus Met, Actoplus Met XR and Duetact.

Depuy Hips Litigation:

On August 24, 2010, DePuy Orthopedics, a subsidiary of Johnson & Johnson, announced a global recall of the ASR™ XL Acetabular System. This total hip replacement has been available in the U.S. since July 2003. Included in the recall was the DePuy ASR™ Hip Resurfacing System, a partial replacement, only approved for use outside the U.S. The recall was initiated following a study which showed that many patients receiving the hip implants suffered from severe pain, stiffness and swelling, followed by popping and grinding sensations, which interfered with their ability to walk, stand, or sit for long periods of time. These symptoms worsened over time resulting in severe disability often requiring a second hip replacement surgery, called revision surgery.

Medical Experts believe that the acetabular cup may be the problem since it is shallower than other proven hip implants. Tiny metal shavings and debris may damage the surrounding tissue causing painful complications and impeding the chances of a successful revision surgery. According to the Recall Pack issued by DePuy, the defects also include component loosening and misalignment, dislocation of the elements, infection, fracture of the bone, metal sensitivity, and pain.

At the time of the ASR recall, 13% of the total hip replacement patients had undergone revision surgery within 5 years of receiving the defective implant. DePuy Orthopedics are also responsible for the DePuy Pinnacle hip implant which has been on the market since 2000. Experts have determined that the DePuy Pinnacle device is also defective. So far, DePuy has avoided a recall by announcing the approval of a new and improved version of the Pinnacle, an industry "silent recall" tactic to remove defective product without bad publicity. The Margolis Firm PC is interested in DePuy ASR and Pinnacle Hips claims.

Lo/Ovral RECALL:

According to the FDA, on January 31, 2012, Pfizer Inc. announced a voluntary recall of its contraceptive pill Lo/Ovral - 28 (norgestrel and ethinyl estradiol) Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) .  An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence.

As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.  The FDA warns that consumers exposed to affected packaging should begin using a non-hormonal form of contraception immediately. The Margolis Firm PC is interested in Lo-Ovral claims.

NuvaRing Litigation:

NuvaRing, manufactured by Merck,  is a combination hormonal contraceptive ring that is inserted into a woman's vagina to prevent pregnancies. The NuvaRing works by releasing a steady dose of the hormones into the bloodstream where it is absorbed through the vaginal wall. Women wear the ring for three weeks and then it is removed for one week. The NuvaRing has been associated with several serious side effects including cardiovascular problems, cardiac arrest, blood clots and even strokes.  The Margolis Firm PC is interested in Merck NuvaRing claims.

Vaginal Mesh Litigation:

Transvaginal mesh and pelvic/bladder support products are used to treat SUI (Stress Urinary Incontinence) and POP (Pelvic Organ Prolapse), conditions that result in a weakening in the pelvic region, a common problem after a hysterectomy or childbirth.

On July 13, 2011, the FDA released a comprehensive medical alert after receiving reports of over 1500 cases of serious injuries in women who underwent procedures using vaginal mesh. Physicians were warned that the risk of injury outweighed the purported benefits and traditional procedures rather than implanation should be the primary course of treatment. According to the FDA, reported complications from the transvaginal placement of the mesh include erosion of the mesh into the vaginal tissue, organ perforation, pain, infection, painful intercourse, and urinary and fecal incontinence. Women have been required to undergo multiple surgeries to remove all the mesh. The Margolis Firm PC is interested in investigating cases concerning vaginal mesh manufactured by American Medical Systems, Bard, Boston Scientific, Caldera, and Johnson & Johnson.